Characterization of skin Th17 transcriptional profiles in psoriatic patients under adalimumab biotherapy

Background In psoriasis, a specific cytokine network has been described to play a central role in the pathophysiology of the disease. Anti-cytokine therapeutic approacheshave been largely developed and TNFα constitutes the main target. Adalimumabis a human anti-TNFα monoclonal antibody that has been reported to demonstrate clinical efficacy and safety, resulting in reversal of epidermal hyperplasiaand cutaneous inflammation.